Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial)Nicolaus Kröger, Théo de Witte, Wolfgang Bethge et al.|Journal of Clinical Oncology|2017Cited by 248
Translational PK/PD for the Development of Novel Antibiotics—A Drug Developer’s PerspectiveCaterina Bissantz, William Stubbings, Andrej Trauner et al.|Antibiotics|2024Cited by 11